small molecule clinical trial intelligence

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension is a PHASE4 clinical asset sponsored by United Therapeutics in Pulmonary Arterial Hypertension. SEO and diligence focus: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis is a PHASE3 clinical asset sponsored by Azafaros B.V. in Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis. SEO and diligence focus: AZ-3102, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration

Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration is a PHASE2 clinical asset sponsored by University Hospital Hradec Kralove in Ischemic Stroke. SEO and diligence focus: Albumin infusion, Placebo Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Implementing and Evaluating ActionADE to Transform Medication Safety Among Patients With an Adverse Drug Event Due to Non-Adherence

Implementing and Evaluating ActionADE to Transform Medication Safety Among Patients With an Adverse Drug Event Due to Non-Adherence is a NA clinical asset sponsored by University of British Columbia in Adverse Drug Event, Non-Adherence, Medication. SEO and diligence focus: ActionADE, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer

The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer is a NA clinical asset sponsored by The Catholic University of Korea in Gastric Cancer. SEO and diligence focus: Lidocaine, normal saline, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma is a PHASE2 clinical asset sponsored by University of Kansas Medical Center in Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma. SEO and diligence focus: Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis is a PHASE2 clinical asset sponsored by NYU Langone Health in Focal Segmental Glomerulosclerosis. SEO and diligence focus: Adalimumab, Lisinopril, losartan, and atorvastatin, galactose, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies is a PHASE1 clinical asset sponsored by National Cancer Institute (NCI) in Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute. SEO and diligence focus: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies is a PHASE1 clinical asset sponsored by AbbVie (prior sponsor, Abbott) in Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia. SEO and diligence focus: ABT-348, ABT-348, ABT-348 and azacitidine, ABT-348, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia is a PHASE2 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia. SEO and diligence focus: Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Idarubicin, Laboratory Biomarker Analysis, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies is a PHASE2 clinical asset sponsored by St. Jude Children's Research Hospital in Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia. SEO and diligence focus: Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology is a PHASE3 clinical asset sponsored by Lantheus Biosciences Ltd. in Alzheimer Disease. SEO and diligence focus: Florbetaben (BAY94-9172), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Mycophenolate Mofetil Therapy for Reduction of the HIV Reservoir

Mycophenolate Mofetil Therapy for Reduction of the HIV Reservoir is a PHASE2 clinical asset sponsored by Fred Hutchinson Cancer Center in Human Immunodeficiency Virus I Infection. SEO and diligence focus: Mycophenolate Mofetil 500Mg Tab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects

An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects is a PHASE1 clinical asset sponsored by Hoffmann-La Roche in Healthy Volunteers. SEO and diligence focus: Risdiplam, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")

Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26") is a PHASE1 clinical asset sponsored by Editas Medicine, Inc. in Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital. SEO and diligence focus: EDIT-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer is a NA clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Liver Cancer. SEO and diligence focus: QY-1-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Mechanisms of Hypoglycemia Associated Autonomic Failure

Mechanisms of Hypoglycemia Associated Autonomic Failure is a PHASE2 clinical asset sponsored by Albert Einstein College of Medicine in Diabetes Mellitus, Hypoglycemia, Autonomic Failure. SEO and diligence focus: naloxone, fructose, exercise, Morphine sulfate, Epinephrine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus

A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus is a PHASE2 clinical asset sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in Type 2 Diabetes Mellitus. SEO and diligence focus: TQ-F3083 capsule 10 mg, TQ-F3083 capsule 20 mg, TQ-F3083 blank analog capsule, TQ-F3083 blank analog capsule, Linagliptin blank analog tablet, Linagliptin tablet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

SAR438544 - Clinical & Exploratory Pharmacology

SAR438544 - Clinical & Exploratory Pharmacology is a PHASE1 clinical asset sponsored by Sanofi in Type 1 Diabetes Mellitus. SEO and diligence focus: SAR438544, r-glucagon, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus

A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Diabetes Mellitus, Type 1. SEO and diligence focus: LY2963016, Lantus, Insulin Lispro, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 is a PHASE1 clinical asset sponsored by Vanderbilt University in Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension. SEO and diligence focus: Trimethaphan, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients is a PHASE3 clinical asset sponsored by Eisai Co., Ltd. in Gastroesophageal Reflux Disease. SEO and diligence focus: Rabeprazole, Rabeprazole, Rabeprazole, Rabeprazole, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh

Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh is a PHASE4 clinical asset sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh in Spondyloarthritis. SEO and diligence focus: Tofacitinib 5 mg,, Etanercept, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer is a PHASE3 clinical asset sponsored by Jiangsu HengRui Medicine Co., Ltd. in Non-Small Cell Lung Cancer With HER2- Mutations. SEO and diligence focus: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics

Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics is a NA clinical asset sponsored by Prisma Health-Upstate in Diabetic Foot Infections. SEO and diligence focus: Surgical incision and drainage of diabetic foot infection, Short course antibiotics, Long course antibiotics, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656 is a PHASE1 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: AZD1656, Gemfibrozil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH)

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH) is a PHASE2 clinical asset sponsored by Central Hospital, Nancy, France in Non-alcoholic Steatohepatitis. SEO and diligence focus: PET scan of 68Ga-FAPI, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Therapeutic Effect and Quality of Life After Local Injection of Steroid VS. Glucose 5% for Carpal Tunnel Syndrome : Double-blinded Clinical Trial

The Therapeutic Effect and Quality of Life After Local Injection of Steroid VS. Glucose 5% for Carpal Tunnel Syndrome : Double-blinded Clinical Trial is a PHASE4 clinical asset sponsored by Assiut University in Carpal Tunnel Syndrome. SEO and diligence focus: Dexamethasone, Glucose Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML）

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML） is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in MDS, AML. SEO and diligence focus: Decitabine, Cytarabine, aclacinomycin, Granulocyte colony-stimulating factor, HLA haploidentical mononuclear cells infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia

A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia is a PHASE1 clinical asset sponsored by Tara Lin in Acute Lymphocytic Leukemia, Acute Myeloid Leukemia. SEO and diligence focus: Daunorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies is a PHASE2 clinical asset sponsored by H. Lee Moffitt Cancer Center and Research Institute in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma. SEO and diligence focus: Fludarabine, Melphalan, Total Body Irradiation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia

Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia is a PHASE2 clinical asset sponsored by Hansoh BioMedical R&D Company in Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease. SEO and diligence focus: HS-20106, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy)

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy) is a PHASE2 clinical asset sponsored by St. Petersburg State Pavlov Medical University in Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia. SEO and diligence focus: Ruxolitinib, Abatacept (Orencia), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers

A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers is a PHASE1 clinical asset sponsored by TauRx Therapeutics Ltd in Alzheimer's Disease. SEO and diligence focus: TRx0037, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease is a PHASE1 clinical asset sponsored by NKGen Biotech, Inc. in Moderate Alzheimer Disease. SEO and diligence focus: SNK01, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease. is a PHASE2 clinical asset sponsored by Stanford University in Alzheimer Disease. SEO and diligence focus: Bumetanide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease is a PHASE1 clinical asset sponsored by University Medical Center Groningen in Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease, Mild Cognitive Impairment. SEO and diligence focus: [18F]MC225, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28 is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Amyotrophic Lateral Sclerosis. SEO and diligence focus: BLZ945, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis is a PHASE1 clinical asset sponsored by Newron Sweden AB in Amyotrophic Lateral Sclerosis. SEO and diligence focus: sNN0029 infusion solution, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) is a PHASE1 clinical asset sponsored by Therapeutic Advances in Childhood Leukemia Consortium in Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute. SEO and diligence focus: EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens

Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Diabetes Mellitus, Type 2. SEO and diligence focus: Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus is a PHASE4 clinical asset sponsored by Command Hospital, India in Type 1 Diabetes. SEO and diligence focus: Insulin, Sitagliptin, Exenatide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Effect of Native GLP-1 on Glucose Metabolism in the CNS During Hyperglycemia in Healthy Young Men Assessed by PET

The Effect of Native GLP-1 on Glucose Metabolism in the CNS During Hyperglycemia in Healthy Young Men Assessed by PET is a PHASE2 clinical asset sponsored by University of Aarhus in Healthy. SEO and diligence focus: native glp-1 (7-36), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes is a PHASE4 clinical asset sponsored by Fundación Fernández-Cruz in Type 2 Diabetes. SEO and diligence focus: Liraglutide + metformin, Glimepiride + metformin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: semaglutide, liraglutide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis is a PHASE3 clinical asset sponsored by Janssen Research & Development, LLC in Colitis, Ulcerative. SEO and diligence focus: Golimumab, Infliximab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) is a PHASE3 clinical asset sponsored by Principia Biopharma, a Sanofi Company in Immune Thrombocytopenia. SEO and diligence focus: Rilzabrutinib, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma

A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma is a PHASE4 clinical asset sponsored by West Penn Allegheny Health System in Asthma. SEO and diligence focus: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases

Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Neuroectodermal Tumor, Brain Metastases, Advanced Cancer. SEO and diligence focus: Valproate, Etoposide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies

A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies is a PHASE2 clinical asset sponsored by Northwestern University in Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV. SEO and diligence focus: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection is a PHASE1 clinical asset sponsored by University of Minnesota in Recurrent Clostridioides Difficile Infection, Colonic Surgery. SEO and diligence focus: Orally administered preparation of fecal microbiota (MTP-101P), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Diabetes Mellitus, Type 2. SEO and diligence focus: MK-1403 + additive coformulation, Placebo + additive coformulation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients is a PHASE3 clinical asset sponsored by Lindner Center of HOPE in Binge Eating Disorder Associated With Obesity. SEO and diligence focus: Zonegran, sugar pill, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit

Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myelogenous Leukemia. SEO and diligence focus: Plerixafor, Clofarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors is a PHASE1 clinical asset sponsored by St. Jude Children's Research Hospital in Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma, Myelodysplastic Syndrome. SEO and diligence focus: Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial

Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial is a PHASE3 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years). SEO and diligence focus: Venetoclax, Azacitidine, Homoharringtonine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies is a PHASE1 clinical asset sponsored by Incyte Corporation in Solid Tumors. SEO and diligence focus: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease

A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease is a PHASE2 clinical asset sponsored by Sunnybrook Health Sciences Centre in Hippocampal Hyperactivation, Prodromal Alzheimer Disease. SEO and diligence focus: Levetiracetam (LEV), Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD is a PHASE2 clinical asset sponsored by AstraZeneca in Alzheimer´s Disease. SEO and diligence focus: AZD1446, Donepezil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE) is a PHASE3 clinical asset sponsored by Eidos Therapeutics, a BridgeBio company in Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis. SEO and diligence focus: Acoramidis (AG10), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer

Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer is a PHASE2 clinical asset sponsored by UNC Lineberger Comprehensive Cancer Center in Bladder Cancer. SEO and diligence focus: Pembrolizumab, Entinostat, Procedure/Surgery, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I) is a PHASE1 clinical asset sponsored by University of Utah in Spinal Muscular Atrophy Type I. SEO and diligence focus: Valproic Acid and Levocarnitine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma is a PHASE1 clinical asset sponsored by Celgene in Multiple Myeloma. SEO and diligence focus: ACY-1215, lenalidomide, Dexamethasone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL

A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL is a PHASE1 clinical asset sponsored by Ruijin Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: ABO2203 Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia is a PHASE1 clinical asset sponsored by Bioray Laboratories in Beta-Thalassemia. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics is a PHASE2 clinical asset sponsored by St. Jude Children's Research Hospital in Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia. SEO and diligence focus: Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Relapsed Adult AML, Refractory AML. SEO and diligence focus: anti-CLL-1 CAR NK cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study) is a PHASE1 clinical asset sponsored by University of Alabama at Birmingham in Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular. SEO and diligence focus: Retifanlimab, INCAGN02385, INCAGN02390, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes is a PHASE2 clinical asset sponsored by University of British Columbia in Type 2 Diabetes, Postprandial Hypotension. SEO and diligence focus: Acarbose, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Type 2 Diabetes, Overweight, Obesity. SEO and diligence focus: Tirzepatide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin detemir, Insulin NPH, Diet/exercise, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia is a PHASE2 clinical asset sponsored by Ain Shams University in Transfusion Dependent Beta Thalassemia. SEO and diligence focus: Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment? is a PHASE3 clinical asset sponsored by Azienda Ospedaliero-Universitaria di Parma in Dysglycemia, Cognitive Deficit. SEO and diligence focus: Exenatide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Effects of Neprilysin on Glucagon-like Peptide-1

The Effects of Neprilysin on Glucagon-like Peptide-1 is a PHASE4 clinical asset sponsored by Nicolai Jacob Wewer Albrechtsen in Diabetes, Heart Failure. SEO and diligence focus: Entresto, Sitagliptin 100mg, Placebos, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning

Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning is a NA clinical asset sponsored by University of Aarhus in Metabolism, Fatty Liver. SEO and diligence focus: Somatropin and pegvisomant, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition: Adaptive, Multicenter, Placebo-controlled, Randomised, Double Blind Trial in a Rare Disorder

Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition: Adaptive, Multicenter, Placebo-controlled, Randomised, Double Blind Trial in a Rare Disorder is a PHASE2 clinical asset sponsored by Assistance Publique Hopitaux De Marseille in Spinal Cord Injury. SEO and diligence focus: Riluzole, Placebo, Blood Samples, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma

A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma is a PHASE2 clinical asset sponsored by Columbia University in Adult T Cell Leukemia/Lymphoma. SEO and diligence focus: Lenalidomide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) is a PHASE3 clinical asset sponsored by Ionis Pharmaceuticals, Inc. in Hereditary Angioedema. SEO and diligence focus: Donidalorsen, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets

Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets is a EARLY_PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Advanced Cancer. SEO and diligence focus: Temsirolimus, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration is a PHASE1 clinical asset sponsored by Fuzhou General Hospital in NSCLC. SEO and diligence focus: QYJD Compound Preparation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL

A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL is a PHASE3 clinical asset sponsored by Sarcoma Alliance for Research through Collaboration in Gastrointestinal Stromal Tumors. SEO and diligence focus: Imatinib mesylate, Imatinib mesylate, Imatinib mesylate, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)

A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in External Genital Warts. SEO and diligence focus: Investigational Treatment, Aldara, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State

A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State is a PHASE1 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: Saxagliptin, Dapagliflozin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study

Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study is a PHASE2 clinical asset sponsored by First Affiliated Hospital of Zhejiang University in Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. SEO and diligence focus: cytarabine+thiotepa+ fludarabine + busulfan, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse

MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse is a PHASE2 clinical asset sponsored by Technische Universität Dresden in Acute Myeloid Leukemia. SEO and diligence focus: Pembrolizumab, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects

A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects is a PHASE1 clinical asset sponsored by Bristol-Myers Squibb in Alzheimer Disease. SEO and diligence focus: Donepezil, BMS-708163, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study is a PHASE2 clinical asset sponsored by Neil M Rofsky, MD, MHA in Alzheimer Disease, Cognitive Decline. SEO and diligence focus: [18F]AV-1451, Positron Emission Tomography, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment.

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment. is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Alzheimer's Disease. SEO and diligence focus: MK-1942, Donepezil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. is a PHASE1 clinical asset sponsored by Nura Bio in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: NB-4746 High dose, NB-4746 Low dose, Placebo, NB-4746 (Dose TBD), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Effects of Telomerase Reactivation With Danazol in Ovarian Function.

Effects of Telomerase Reactivation With Danazol in Ovarian Function. is a NA clinical asset sponsored by IVI Madrid in Ovarian Reserve. SEO and diligence focus: Danazol/Placebo, Without intervention, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial

The SAVE-MORE trial, sponsored by the Hellenic Institute for the Study of Sepsis, evaluates the efficacy and safety of anakinra, an IL-1 receptor antagonist, in patients with severe respiratory failure due to COVID-19. Given the significant reduction in severe respiratory failure incidence and mortality rates observed in the trial, anakinra may position itself as a critical therapeutic option in the COVID-19 treatment landscape. The market for COVID-19 therapeutics remains competitive, with various agents under investigation; however, the unique biomarker-guided approach using suPAR may provide a differentiated value proposition. Companies should consider potential partnerships or licensing opportunities to leverage the findings and expedite market entry.

Matched by modality_normalized: small molecule

A Phase 2 Clinical Trial to Test the Safety and Efficacy of Etravirine in Friedreich Ataxia Patients

Etravirine, an FDA-approved non-nucleoside reverse transcriptase inhibitor for HIV, is being repositioned for the treatment of Friedreich Ataxia (FA), a rare neurodegenerative disorder with no current approved therapies. The trial aims to assess its safety and efficacy in a small cohort of FA patients, potentially opening a new therapeutic avenue in a niche market. Given the favorable safety profile of Etravirine and the unmet medical need in FA, successful outcomes could lead to significant market opportunities, particularly in rare disease segments. The competitive landscape remains limited due to the rarity of FA, but diligence should focus on ongoing and future studies targeting Frataxin and related pathways.

Matched by modality_normalized: small molecule

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CS1+ Multiple Myeloma

The CS1-CAR T therapy is positioned within the competitive landscape of advanced therapies for relapsed or refractory multiple myeloma, a market projected to grow significantly due to increasing incidence rates and the need for effective treatment options. The trial, sponsored by City of Hope Medical Center, aims to establish safety and dosing parameters, which are critical for subsequent phases and potential commercialization. The suspension of the trial due to slow accrual raises concerns about patient recruitment strategies and may impact timelines for market entry. The collaboration with the National Cancer Institute (NCI) could enhance credibility and provide additional resources for future development. The success of this therapy could position City of Hope as a leader in CAR T-cell therapies, particularly in the niche of CS1-positive multiple myeloma.

A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients

This clinical trial, sponsored by the Chinese PLA General Hospital, aims to evaluate the efficacy and safety of chidamide as a bridging therapy in CAR-T treated patients with recurrent or refractory B-cell NHL. The study targets a significant unmet need in the oncology market, particularly for patients exhibiting low NOXA expression, which is associated with CAR-T resistance. The competitive landscape includes existing CAR-T therapies, but the integration of chidamide may provide a differentiated approach to enhance treatment outcomes. Given the increasing prevalence of NHL and the growing adoption of CAR-T therapies, successful results could position the sponsor favorably within the expanding biopharmaceutical market focused on hematologic malignancies.

Matched by modality_normalized: small molecule

A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus

Eli Lilly's tirzepatide is positioned to compete in the growing Type 2 diabetes market, which is projected to reach $70 billion by 2025. The drug's once-weekly administration and dual receptor action may provide a competitive edge over existing therapies such as dulaglutide. Successful outcomes from this trial could enhance Eli Lilly's portfolio and market share, particularly against other GLP-1 receptor agonists. The trial's completion and subsequent data readouts will be critical for investor confidence and potential partnerships or licensing opportunities.

Matched by modality_normalized: small molecule

Effect of INitial Combination Therapy With GEmigliptin and Metformin on Microbiota Change and Glycemic Control in patientS With Type 2 DIabetes aNd ObEsity (INTESTINE Study)

The INTESTINE Study evaluates the efficacy of gemigliptin, a DPP-4 inhibitor, in combination with metformin, against glimepiride and metformin in treating obese patients with type 2 diabetes. Given the increasing prevalence of diabetes and obesity, this study addresses a significant market need. If successful, gemigliptin could enhance its competitive positioning against established therapies, particularly in the context of combination therapies that leverage gut microbiota modulation. The findings may also support further development and marketing strategies for gemigliptin, potentially expanding its market share in the diabetes treatment landscape.

Matched by modality_normalized: small molecule

Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

The REVISE-Diabesity trial investigates the efficacy of the Endobarrier device in conjunction with Liraglutide for treating obesity and type 2 diabetes in patients unresponsive to conventional therapies. Given the rising prevalence of obesity and T2DM, this study addresses a significant unmet medical need, potentially positioning the Endobarrier as a viable non-surgical alternative to bariatric surgery. The outcomes could enhance market competitiveness against existing GLP-1 receptor agonists and other obesity treatments, while also informing future product development strategies. Stakeholders should consider the implications of successful results on market access, reimbursement strategies, and potential partnerships for commercialization.

Matched by modality_normalized: small molecule

Characterizing Pyoderma Gangrenosum Lesion Regression and Remission by IL-36 Receptor Targeting With Spesolimab

Spesolimab, an IL-36 receptor antagonist, is being investigated for the treatment of moderate to severe pyoderma gangrenosum (PG), a rare and debilitating autoimmune skin condition. The study's termination indicates a strategic pivot towards a multicenter national study, which may enhance data robustness and market appeal. The competitive landscape includes existing therapies for PG, but no gold standard treatment currently exists, presenting a significant market opportunity for effective therapies. The asset's collaboration with Boehringer Ingelheim may strengthen its development and commercialization prospects, particularly in expanding indications for IL-36 targeting therapies.

Matched by modality_normalized: small molecule

Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Pediatric Patients With Language Dysfunction : A Follow up Study

The study, sponsored by Ain Shams University, investigates the relationship between sleep EEG changes and language dysfunction in children aged 3 to 10 years. Given the increasing prevalence of language disorders and the potential overlap with epilepsy, this research could address a significant unmet medical need in pediatric neurology. The findings may lead to novel therapeutic strategies, particularly the use of corticosteroids like methylprednisolone and prednisolone, which could enhance language development in affected children. The market for pediatric neurological treatments is growing, and successful outcomes could position Ain Shams University as a key player in this niche, potentially attracting partnerships or licensing opportunities with larger pharmaceutical companies. However, the competitive landscape includes established therapies for language disorders and epilepsy, necessitating careful market positioning and differentiation strategies.

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer

The Phase III trial of Atezolizumab in combination with chemotherapy for operable Stage II-III Triple Negative Breast Cancer (TNBC) was terminated after an interim analysis indicated that the primary endpoint of invasive disease-free survival (iDFS) crossed a pre-specified futility boundary. This outcome suggests limited commercial viability for this combination therapy in the TNBC market, which is highly competitive with existing therapies. The termination may impact Hoffmann-La Roche's strategic positioning in the immuno-oncology space, particularly against other PD-1/PD-L1 inhibitors and chemotherapy regimens. Stakeholders should assess the implications for future development and potential reallocation of resources towards more promising assets.

Matched by modality_normalized: small molecule